We assessed the effect standard-dose induction chemotherapy and tandem cycles of high-dose chemotherapy (HDC) have on outcomes in metastatic breast cancer. One hundred and one women with metastatic breast cancer were enrolled in two non-randomized phase II studies. The first group of 64 patients (induction group) received four cycles of docetaxel 75 mg/m 2 and doxorubicin 50 mg/m 2 . The next 37 patients did not receive induction (no induction group). Both groups received two (tandem) cycles of HDC. Blood-derived stem cells were collected after the first HDC cycle, processed using CD34 + cell selection and then reinfused after the second HDC cycle. Outcomes were compared between the two groups and also to patients participating in the Philadelphia (inter-group) randomized metastatic breast cancer transplant trial (PBT-01). Intent-to-treat analysis revealed no significant differences in complete response rates (37.5% vs 27%; P = 0.20), overall response (75% vs 71%), median progression free survival (PFS) (11.9 vs 8 months; P = 0.24) and overall survival (OS) (Ͼ36 vs 25 months; P = 0.16), in the induction vs no induction groups, respectively. Adjusting for differences in known baseline characteristics, induction group patients were found to have significantly longer PFS (P = 0.002), OS (P = 0.01) and more frequent conversion from a partial to complete response (58% vs р13%, P р 0.0002) when compared with PBT-01 patients. Induction chemotherapy administered prior to tandem cycles of HDC does not appear to adversely affect outcomes in metastatic breast cancer patients. Outcomes in our induction group also compare favorably with those observed in PBT-01 and warrant further clinical investigation. Bone Marrow Transplantation (2001) 27, 1245-1253.
Chemotherapy agents administered to patients with metastatic breast cancer in standard doses, alone or in combination, result in a low complete response rate (CR) (8-20%), short response duration (median 5-14 months) and limited overall survival (median 14-24 months). [1] [2] [3] Several pilot phase II trials using high-dose chemotherapy (HDC) supported by autologous hematopoietic stem cell transplantation appeared to result in superior outcomes, including a greater than expected percentage of patients who were disease-free (7-18%) after 5 years of follow-up. 4, 5 However, results from the Philadelphia bone marrow transplant group (inter-group) phase III randomized trial (PBT-01) support the contention that patient selection bias, and not the efficacy of HDC, results in the apparent outcome advantage observed in patients with advanced breast cancer enrolled in HDC trials. [6] [7] [8] [9] In PBT-01, a single cycle of HDC with unpurged stem cell rescue failed to improve survival over standard-dose therapy. This outcome, however, may have been a consequence of several factors. Reports of 2-year disease-free survival rates approaching 60% in two phase II trials of multiple cycles of HDC administered in rapid succession to patients with metastatic breast cancer indicate that one cycle of HDC may not be optimal. 10, 11 The superiority of multiple cycles of HDC would be in accordance with transplantation results observed in patients with germ cell malignancies. [12] [13] [14] The role of standard-dose induction chemotherapy in autologous transplantation is also unclear. In a phase III trial, patients with metastatic breast cancer who achieved a CR following standard dose induction chemotherapy were randomized between immediate HDC or HDC at the time of relapse. 15 A trend towards superior median overall survival was observed in the delayed HDC treatment group (34 vs 24 months; P = 0.08). In PBT-01, standard-dose chemotherapy was administered to patients immediately prior to HDC and therefore may have adversely affected survival. In addition, no effort was made in PBT-01 to detect or eliminate tumor cells contained in the stem cell products. Malignant cell contamination is common in blood stem cell products collected from patients with metastatic breast cancer. 16 Furthermore, gene marking studies illustrate that contaminating malignant cells are cap-able of contributing to disease relapse, raising the possibility that reinfusion of contaminated stem cell products may also reduce the efficacy of HDC. 17, 18 This report describes our experience addressing the effects of standard-dose induction chemotherapy, two rapidly sequenced ('tandem') cycles of HDC and purging using CD34
+ selection in the treatment of patients with metastatic breast cancer. We discuss the results of two nonrandomized phase II trials conducted by four ECOG institutions that also participated in PBT-01, and provide a comparison of outcomes between these trials and PBT-01.
Patients and methods

Patients
Between February 1997 and November 1998, 101 women with histologically documented epithelial carcinoma of the breast metastatic to any organ (except brain), including ipsilateral supraclavicular lymph nodes and chest wall were enrolled consecutively into one of two phase II studies conducted at four ECOG institutions. Eligibility criteria were identical for both studies. Institutions closed accrual (at different time intervals) to the induction group study prior to initiating accrual to the no induction group study to avoid patient selection bias. The patients had not received prior chemotherapy for treatment of metastatic breast cancer, but had failed hormone therapy (if estrogen receptor (ER) positive without extensive visceral disease). Patients aged у18 years but р65 years, with evaluable (bone only) or measurable disease and no prior adjuvant chemotherapy within 6 months of study were eligible for enrollment. All patients provided written informed consent for protocols that had been approved by the institutional review board of each institution. Prior to enrollment, all patients were required to have a Karnofsky performance status (KPS) у70, serum total bilirubin Ͻ3.0 mg/dl, cardiac ejection fraction Ͼ40%, no prior history of a previous malignancy (except basal cell skin cancer), prior cumulative adriamycin-equivalent dose р360 mg/m 2 and be seronegative for the human immunodeficiency virus. After enrollment, all patients were scheduled to complete all the components of chemotherapy, including those who exhibited disease progression during any phase of therapy. Patients were removed from study only if they had an inadequate stem cell number after cell selection (Ͻ0.75 × 10 6 /kg) or if they developed life-threatening vital organ dysfunction due to disease progression or therapy.
The first 64 patients enrolled (November 1997-August 1998) were to receive four cycles of standard-dose induction chemotherapy followed by two cycles of HDC. The next 37 patients enrolled (October 1997-November 1998) were to receive the identical two cycles of HDC without prior induction chemotherapy. In addition to providing cytoreduction, the first cycle of HDC was used to mobilize blood-derived hematopoietic stem cells, which were collected (Fenwall CS 3000, Deerfield, IL, USA, or Cobe Spectra, Lakewood, CO, USA) and CD34
+ cell selected (Isolex, Nexell Therapeutics, Irvine, CA, USA). CD34 + selected stem cells were reinfused after the second cycle of HDC.
Induction chemotherapy
Standard-dose chemotherapy, given as induction, consisted of doxorubicin 50 mg/m 2 administered as an intravenous bolus followed immediately by docetaxel 75 mg/m 2 infused over 1 h. G-CSF (5 g/kg) was administered subcutaneously, commencing 24 h after treatment and continuing for 10-14 days. Induction chemotherapy was administered every 21 days for four cycles. Single agent docetaxel was administered if a lifetime accumulated doxorubicin dose exceeded 500 mg/m 2 . Dexamethasone prophylaxis (8 mg p.o., twice a day) was started the day prior to docetaxel therapy and was administered for five consecutive doses.
Tandem cycles of HDC and CD34
+ selected stem cell procurement For patients receiving induction chemotherapy, the first cycle of HDC was administered within 21 days of completion of standard-dose doxorubicin and docetaxel. Patients in both groups received cyclophosphamide 2500 mg/m 2 intravenously daily over 2 h for 2 days, and etoposide 500 mg/m 2 (over 4 h) and cisplatin 40 mg/m 2 (over 1 h) both administered intravenously daily for 3 days. Hydration, anti-emetic and antibiotic prophylaxis followed standard medical practice for HDC administration. G-CSF (5 g/kg subcutaneously twice a day) was initiated 24 h after completion of HDC and was continued until the final day of apheresis. Daily 10-20 liter aphereses began upon achievement of a neutrophil count у1000 cells/l, coincident with a rising platelet count. Prior to CD34
+ cell selection, a sample of the apheresis product was assessed for contaminating malignant cells using immunocytochemistry (ICC). 19 Peripheral blood mononuclear cells were selected using positive (ie CD34 + cell selection) or positive followed by negative selection (ie breast cancer cell selection) as described elsewhere. 20 A minimum of 0.75 × 10 6 /kg CD34 + selected blood stem cells was required to proceed on study.
The selected stem cells were assessed for malignant cell contamination using ICC and cryopreserved using a modification of a previously described technique. 21 Within 35 days of the first cycle of HDC, patients received the second HDC cycle, which consisted of cyclophosphamide 6000 mg/m 2 , thiotepa 500 mg/m 2 and carboplatin 800 mg/m 2 administered over 3-4 days. 4 Following a 2-day rest period, selected stem cells were infused and G-CSF (5 g/kg) was initiated and continued until an absolute neutrophil count of 1000 cells/l for 3 days or 5000 cells/l for 1 day was achieved. All patients in the induction group and the first 17 in the no induction group received positively selected stem cells. The remaining 20 no induction group patients received stem cells processed by positive followed by negative selection. All supportive measures were consistent with routine medical practice.
Post-HDC therapy
All patients, regardless of estrogen or progesterone status, received anastrozole (1 mg p.o. daily) and patients with bone involvement received pamidronate disodium monthly (90 mg intravenously), both until disease progression. Radi-ation therapy was administered to sites of local bulky (у5 cm) disease.
Response assessment
Response to therapy was assessed using external imaging techniques (total body CT scan, bone scan and bone survey) within 4 weeks of enrollment and within 1 to 3 weeks after each component of therapy. Restaging was scheduled to occur at 8 weeks, and then during months 6, 12, 18, 36, 48 and 60 following completion of the second HDC cycle. Symptomatic patients were restaged immediately. Response definitions include: (1) Complete response (CR): resolution of all disease sites. Bone lytic lesions will have recalcified. Complete resolution of soft tissue disease and evidence of bone healing on X-ray, regardless of bone scan result except for new lesions, in patients with disease of bone and soft tissue. Complete resolution on X-ray and bone scan for patients with bone only disease. (2) Partial response (PR): у50% and Ͻ100% reduction in bidimensional measurable disease. Bone lesion healing on X-ray and static on bone scan for 8 or more weeks in bone only disease. (3) Some response (SR): у25% and Ͻ50% reduction in bidimensional measurable disease. Static bone lesions on X-ray and bone scan for 8 or more weeks. Mixed response (ie Ͼ50% reduction in soft tissue disease but no more than two new bone lesions on X-ray or bone scan). (4) No response (NR): Ͻ25% reduction and Ͻ25% growth in bidimensional measurable disease and no more than two new lesions on bone scan or X-ray. (5) Progressive disease (PD): у25% growth of bidimensional measurable disease. Three or more new lesions on X-ray or bone scan. Any new soft tissue/visceral disease.
Toxicity was graded according to the NCI common toxicity criteria.
Statistical analysis
Comparison of induction and no induction group patients: Patient characteristics assessed at the time of study entry were compared between induction and no induction patient groups. Disease distribution included patients with: (1) viscera/soft tissue; (2) bone and viscera/soft tissue; and (3) bone only. There were five possible sites of disease: bone, bone marrow, liver, lung and other soft tissue. Patients were segregated by age (р vs Ͼ45 years), disease-free interval (р or Ͼ18 months), estrogen receptor (ER) status, HER2/neu status, KPS assessed during initial registration (Ͻ90 vs у90) and treatment with adjuvant chemotherapy and adjuvant anthracyclines. PFS and OS were compared using Kaplan-Meier curves with equality tested using log-rank statistics. Multivariate analysis was performed to determine and adjust for significant predictors of response using logistic regression and survival using Cox proportional hazards regression. Variables with P р 0.10 were included in the analysis model and reported. Kaplan-Meier estimates of PFS and overall survival were compared in the induction group with patients stratified by response to induction and ER status.
In view of the modest size of our study we addressed the possibility that a larger study would have shown no
Bone Marrow Transplantation induction to be superior to induction. We used Bayesian methodology, conditioning on the information available in the study and assuming exponential survival and noninformative prior distributions, to generate additional patients from both groups. 22 Calculations use simulations with 10 000 iterations.
Comparison of PBT-01 to induction and no induction group patients:
The PBT-01 data set was re-analyzed with responses assessed according to the definitions used in our two phase II studies. Baseline characteristics and marginal response rates used Fisher's exact test. 23 Survival rates were estimated using the product limit method and compared using a log rank test. 24 We adjusted for any differences in patient characteristics in the two groups using logistic regression analysis for response rates and Cox proportional hazards model for survival. 25, 26 In the regression models, factors including disease distribution, number of involved sites, disease-free interval, prior chemotherapy (with and without anthracyclines), liver involvement, ER status and age were considered with a backward elimination procedure used to remove non-significant variables, but with study group retained regardless of significance.
Results
Patients characteristics
One hundred and one patients with metastatic breast cancer were enrolled in two non-randomized phase II trials. Patients received either induction standard-dose chemotherapy (n = 64) or no induction (n = 37), followed by tandem cycles of HDC with CD34
+ selected blood stem cell support provided after the second HDC cycle. Patient characteristics are listed in Table 1 . The groups were similar with regard to patient age, number of disease sites and distribution, presence of liver metastasis, disease-free interval, ER status and HER 2/neu status. The no induction group had a significantly greater proportion of patients receiving adjuvant chemotherapy (78% vs 56%; P = 0.02), adjuvant anthracyclines (41% vs 30%; P = 0.03) and a greater percentage of patients with a KPS of у90 (81% vs 58%; P = 0.003).
Response to standard-dose induction chemotherapy
All 64 induction group patients were evaluable for response. Seven patients (11%) achieved a CR, 28 (44%) a PR and eight (12%) progressed during induction chemotherapy. The overall objective response rate was 55%. Twenty-two patients experienced grade III-IV toxicities including gastrointestinal (6), neutropenic sepsis (5), neurologic (2), allergy (1), pulmonary (3), cardiac (2), renal (1) and cytopenias (2) .
Response to sequential high-dose chemotherapy
Fifty-six induction and 37 no induction group patients completed the first cycle of HDC. Eight patients who received induction were removed from study prior to the first cycle of HDC due to disease progression (2 in CNS and 2 in soft tissue), pneumonitis (1), cardiac dysfunction (2) and denial of insurance benefits (1). One additional patient was removed after the first HDC cycle due to an inadequate stem cell collection and refused a response assessment. Thus, 55 induction and all 37 no induction group patients were evaluable for a response after the first HDC cycle (Table 2) . Eight induction and two no induction group patients were observed to be in CR. A PR was observed in 28 induction and eight no induction group patients. Four and one of the induction and no induction group patients, respectively, progressed shortly after the first HDC cycle. Fifty-two induction and all 37 no induction group patients received the second cycle of HDC. Four induction group patients did not continue therapy because of disease progression (2, CNS) and inadequate blood stem cell collections (2). One patient from each group expired soon after the second HDC cycle and was not re-assessed for a response. Thus, 51 induction and 36 no induction patients were evaluable for a response after the second HDC cycle (Table 2) . Twenty-three induction and nine no induction group patients were observed to be in CR (P Ͻ 0.05). Sixteen induction and 13 no induction group patients were observed to be in PR. Disease progression occurred within 8 weeks of the second HDC cycle in nine and eight of induction and no induction group patients, respectively. Patients in each group (58% vs 67%) experienced a similar cumulative incidence of grade III-IV non-hematologic toxicity to both cycles of HDC. Three patients expired (3.4%), two in the induction group (disseminated candida and liver failure with documented metastasis on post-mortem) and one in the no induction group (liver failure with extensive pre-treatment liver metastasis), within 30 days of receiving the second cycle of HDC. Table 3 lists the PFS and overall survival of induction group patients (n = 64) segregated by response to induction chemotherapy. Due to the small sample size of the response subgroups, standard errors were large, so the subgroups were analyzed as ordered variables. Univariate proportional hazards regression analysis revealed that a better response to induction chemotherapy was associated with a significant increase in PFS (P Ͻ 0.0001) and overall survival (P = 0.05). Of note, at 24 months of follow-up, patients achieving a PR, SR or NR to induction experienced similar PFS (17-25%) and none with PD during induction were diseasefree (Figure 1) .
Effect of response to induction chemotherapy and ER status on outcomes
Accounting for ER status using proportional hazards modeling, response to induction chemotherapy was no longer a predictor of overall survival (P = 0.27). ER positive patients had a significantly greater overall survival (P = 0.0019) and were found to have a significantly greater likelihood of responding to induction chemotherapy (P = 0.003). In contrast, response to induction chemotherapy remained a significant predictor of PFS (P = 0.0007) regardless of ER status (P = 0.056). When patients were analyzed by ER status, a better response to induction chemotherapy continued to be associated with improved PFS and overall survival in both ER positive and negative patient subgroups.
Effect of induction on survival
Due to the sequencing of our phase II trials, patients receiving induction chemotherapy have longer follow-up (induction: median 34 months (range, 21-38 months)) than no induction group patients (26 months (range, 18-30 months)). Using an intent-to-treat analysis there were no significant differences between groups with regard to rates of CR (37.5% vs 27%; P = 0.20) or overall response (75% vs 71%). In addition, as shown in Figure 2 , median PFS and overall survival were not significantly different between the groups. However, median PFS was significantly greater in the induction group (14.4 months vs 8.0 months; P = 0.02) and the relative risk of disease progression was significantly lower (RR 0.56; P = 0.024), when patients from both groups who received the second cycle of HDC were compared. Accounting for all 101 patients (noting the differing median follow-up times), 39 (61%) induction patients were alive and 17 (26.5%) were progression-free at the time of this analysis. Twenty-one (57%) no induction group patients were alive and 10 (27%) were progression-free. The relatively small sample sizes of our study group patients prompted the construction of a Bayesian predictive probability model to assess the effect of induction chemotherapy had our study been larger. We assumed 500 induction group patients were compared to 500 no induction group patients (including existing patients). 22 The probability that the no induction group would be found to have significantly better PFS or overall survival was no greater than 4%.
Multivariate analysis
Patient age, treatment group assignment, ER status, number of metastatic sites, liver involvement, prior chemotherapy, prior anthracyclines, disease-free interval, HER 2/neu status, and KPS (assessed during initial registration) were analyzed in a multivariate analysis to determine predictors of outcome. The relative risk (RR) of death was estimated to be decreased by 73% in ER positive patients (0.27 RR 0.14-0.50; P = 0.0001) and 24% in induction group patients (0.76 RR 0.55-1.06; P = 0.10). Disease progression was Bone Marrow Transplantation 
Comparison to PBT-01 outcome
Baseline characteristics: Baseline characteristics were compared between the 64 patients enrolled in our induction group and 516 evaluable patients in PBT-01. The distribution of disease sites and number of involved sites of disease were similar between studies. A greater percentage of our patients had a disease-free interval of less than 18 months (45% vs 33%: P = 0.03) and were ER positive (72% vs 50%; P = 0.0008). Other characteristics including prior exposure to anthracyclines, age and the presence of liver involvement were similar.
Response to induction chemotherapy:
The primary PBT-01 data set was re-analyzed by ECOG statisticians in order to assess responses using the same definitions as in our study. Listed in Table 4 are the rates of complete and partial responses to induction chemotherapy, which were similar for the two studies. In logistic regression analysis of combined induction responses (CR or PR) adjusting for differences in significant baseline factors, differences between PBT-01 and induction group patients were not significant (P = 0.29). The proportion of patients progressing during induction chemotherapy was higher in PBT-01 (31% vs 12%) and the Kaplan-Meier estimate of the proportion pro- Number of patients (%) achieving the noted response to induction standard-dose chemotherapy.
gressing within 4 months of entry was 21% for PBT-01 and 9% for our patients (P Ͻ 0.05).
Conversion rates to CR:
Conversion from a PR obtained by treatment with standard-dose induction chemotherapy to a CR obtained by treatment with HDC was substantially greater in our patients following tandem cycles of HDC (P Ͻ 0.0001). Using logistic regression to adjust for differences in the effects of baseline characteristics, the differences in conversion to CR for the induction PR subgroups remain significant. In our study, 24 patients achieved a PR as a result of induction chemotherapy. Fourteen of these patients went on to achieve a CR following tandem cycles of HDC (conversion rate: 58% (14/24)), which appeared to be substantially greater (P р 0.0002) than either group in PBT-01 randomized to receive HDC or maintenance chemotherapy after achieving a PR following induction chemotherapy (PBT-01-BMT arm 13% (9/67) and PBT-01-CMF arm 11% (7/64)).
Survival comparisons:
Using a proportional hazards model for survival, adjusting for significant differences in baseline characteristics, induction group patients again were found to have significantly longer overall survival (P = 0.01) than patients in PBT-01 with the mortality hazard rate estimated to be 44% lower (95% confidence interval (CI) of 15% to 63%). Induction group patients also had a significantly greater PFS (P = 0.002) with the progression hazard rate estimated to be 40% lower (95% CI, 17% to 57%).
Further analysis was conducted to compare outcomes of patients from both our groups who completed HDC, to eligible patients who were randomized to receive HDC in PBT-01. Ninety-six of the 101 eligible patients proceeded on to HDC in PBT-01. In this analysis, induction group patients included only those who did not progress during induction (CR, PR, SR and NR). For overall survival, fitting proportional hazards models to adjust for differences in baseline characteristics and response to induction, the estimated reduction in the mortality hazard of our induction group was 40% (P = 0.07; 95% CI, −66%, +5%). With regard to PFS, the estimated reduction in the progression hazard was 35% (P = 0.04; 95% CI, 1%, 57%). In contrast, no induction group patients experienced similar overall survival (P = 0.85) and PFS (P = 0.85) compared with transplant patients in PBT-01.
Effect of selection on tumor cell depletion and hematopoietic engraftment
A total of 130 aphereses were performed on 88 patients. One hundred positive selections and 20 positive/negative selections were performed. Ninety-six products were tested and 11 were found to be ICC-positive pre-selection (incidence: 11.4% (11/96)). While two of 10 products (20%) showed persistent contamination after positive selection, none of the products tested were found to have malignant cells after negative selection. The dose of CD34 + blood stem cells infused ranged from 0.76 × 10 6 to 27.7 × 10 6 cells/kg. There were no significant differences in days to recovery to 500 neutrophils/l (median 9 days; range 8-14 days), 1000 neutrophils/l (median 10 days; range 8-21 days) or 50 000 platelets/l (median 17 days; range 11-149 days) among any groups of patients.
Discussion
In this comparison between two non-randomized phase II multi-center trials we have demonstrated that four cycles of docetaxel and doxorubicin administered in standard doses (induction chemotherapy) did not adversely affect outcomes in patients with metastatic breast cancer treated with autologous transplant. In addition, patients who achieved a PR following induction chemotherapy were observed to have a greater rate of conversion to CR after tandem cycles of HDC (induction group patients) when compared with patients in PBT-01 who received either a single cycle of HDC or maintenance CMF (58% vs 11-13%). Moreover, following induction chemotherapy, administration of tandem cycles of HDC supported by CD34 + selected stem cells compared with a single cycle of HDC (PBT-01) appeared to be associated with a significant decrease in the rate of progression (40%, P = 0.002) and death (44%, P = 0.01), even after adjusting for significant differences in baseline characteristics between studies.
Induction standard-dose chemotherapy administered immediately prior to HDC has been proposed to adversely affect outcome by precluding patients who progress during induction from receiving HDC and by inducing a state of chemotherapy resistance, regardless of the degree of response to induction. The findings in our study, however, do not support either of these proposals. In an intent-totreat analysis with only 81% (52/64) of induction group patients actually completing HDC, the rate of CR, median PFS and overall survival were similar between our induction and no induction groups. Furthermore, in a comparison of induction and no induction group patients who completed both cycles of HDC, the relative risk of disease progression was found to be significantly lower (RR 0.56, P = 0.024) and the rate of CR (45% vs 25%, P Ͻ 0.05) and median PFS (14.4 months vs 8.0 months, P = 0.02) were significantly greater in the induction group.
Our statistical comparisons do not have the same strength of interpretation, as do those from prospective randomized studies. However, comparisons of the induction and no induction groups have statistical credibility because all eligible patients were enrolled, eligibility criteria were identBone Marrow Transplantation ical, the studies were conducted at the same institutions and within a relatively close time period. In addition, patient characteristics were balanced for variables identified in multivariate analysis to be predictive of outcomes. While potentially less valid, the comparison between our patients and those participating in PBT-01 was reported after adjusting for known differences in baseline characteristics using the same response definitions. Prospective randomized trials are now needed to confirm the validity of these observations.
To limit the potential of selection bias, factors identified in multivariate analysis that predict survival outcomes were compared between the induction and no induction groups. These were found to be similar to those reported by the Autologous Blood and Marrow Transplant Registry (ABMTR) and were observed to be balanced between the groups. [27] [28] [29] The likelihood of observing an adverse effect on outcome due to induction chemotherapy was found to be no more than 4% using a statistical model of a 1000 patient trial. 22 Overall, a better response to induction chemotherapy was associated with a significant increase in PFS (P Ͻ 0.0001) and overall survival (P = 0.05). Furthermore, patients treated with tandem HDC without induction chemotherapy (no induction group), experienced similar PFS (P = 0.35) and overall survival (P = 0.06) to patients participating in PBT-01. Collectively, these findings further support the benefit of induction chemotherapy.
The low rate of conversion from induction chemotherapy-induced PR to single cycle HDC induced CR observed in PBT-01 was supported by the results of our study. Of our 28 patients who achieved a PR following induction, only one patient (3.6%) converted to a CR after the first cycle of HDC. Other trials of a single cycle of HDC have reported much higher conversion rates, ranging between 20 and 60%. [30] [31] [32] The low conversion rate observed following the first cycle of HDC in our trial may be explained in part by the chemotherapy agents used (CEP) and the relatively short interval (3 weeks) between treatment and the response assessment. 33 The value of HDC in the setting of metastatic breast cancer remains controversial and may in fact be limited, as noted in the ABMTR analysis, to specific patient subsets. In a small prospective randomized study (PEGASE-04), 61 patients responding to standard-dose chemotherapy (PR or CR) were treated with one cycle of HDC or continued standard-dose chemotherapy. 34 While overall survival was similar at 5 years of follow-up, median PFS was significantly greater in the HDC arm (26.9 vs 15.7 months respectively, P = 0.04). In another large retrospective study, outcomes of 635 patients receiving standard-dose therapy were compared to 441 patients receiving a single cycle of HDC after demonstrating a response to induction chemotherapy. 35 Controlling for significant prognostic factors, patients receiving HDC had a significantly greater survival at 5 years of follow-up (23%, 95% CI, 17-29 vs 15% 95% CI, 11-19%; P = 0.03). In all of these studies, response to induction chemotherapy was found to predict outcome. In our study, similar to findings in the ABMTR analysis, patients achieving less than a CR but not progressing during induction chemotherapy were found to have similar PFS outcomes and thus can be grouped together for the purpose of outcome analysis. Of note, based on our data, there is no basis to preclude these patients (SR and NR after induction chemotherapy) from participating in future trials of HDC.
The effect of CD34 + cell selection on HDC outcomes in breast cancer patients remains uncertain. In a multicenter trial of 205 patients with advanced stage breast cancer (stage II-IV), patients were randomized to receive CD34 + breast cancer cell negative selected stem cells (positive/negative selection) or unselected stem cells after HDC, using the Isolex 300/300i device. 36 Engraftment was similar between groups and PFS was not different in the subset of patients with stage III-B/IV disease. However, patients with stage II/IIIA disease who received selected stem cells had a significantly greater PFS compared to the unselected group (P = 0.04). Thus, patients with minimal disease at the time of stem cell harvest may benefit by CD34 + cell selection. Eighty-six percent of our induction group patients who achieved a CR to induction remain alive and disease-free at 2 years follow-up. Acknowledging the small sample size (7/64), it remains plausible that cell selection added to the observed benefit of induction chemotherapy and tandem HDC in the CR subgroup, warranting further trials of selection. The relative efficacy and safety of positive vs positive followed by negative selection observed in this trial are reported elsewhere. 20 The outcomes of patients in both arms of PBT-01 were disappointing. In an intent-to-treat analysis at a median follow-up of 37 months, median survival ranged between 24-26 months and the 3-year progression-free survival was only 6-12%. In our study, also using an intent-to-treat analysis, at a median follow-up of 34 months, 61% of induction group patients were alive and 26.5% were progression-free. Achieving a complete response would appear to be the necessary first step to obtain prolonged PFS and improved overall survival in patients with metastatic breast cancer. In our study, 37.5% of induction group patients achieved a CR (intent-to-treat analysis) with an observed high rate of conversion from PR following induction to CR after tandem HDC (58%). Recent studies have suggested that HDC, by providing a setting of minimal disease, decreases the ability of tumor cells to induced T cell tolerance. In addition, peptide antigen and whole tumor cell vaccines administered in the post-HDC setting appear to be capable of skewing the T cell repertoire toward a specific antigenic response. [37] [38] [39] [40] Longer follow-up and prospective randomized trials are needed to determine the long-term benefit if any, of our sequenced treatment approach (ie induction chemotherapy-tandem HDC-CD34 + cell selection) for metastatic breast cancer patients. In fact, other investigators have not found significant differences in outcomes between single and tandem/multi-high dose chemotherapy cycles, regardless of induction chemotherapy. 41, 42 However, in the short-term our sequenced therapy may provide a unique opportunity to study the efficacy of strategies directed against minimal residual disease, including tumor antigenspecific vaccines.
